55 IPOs raised $15.5 billion in the most active July since 1999 and the biggest for proceeds ever. The month’s IPOs were joined by 26 SPACs. Healthcare was the most active sector with 25 IPOs, mostly biotechs, as well as medical device makers and health...read more
IPO activity continued at a record pace this past week with 19 IPOs, marking the fourth week in 2021 with at least 17 US IPOs, the most since the year 2000. With the August lull around the corner, the pipeline saw less activity than usual; five IPOs and 13 SPACs...read more
HCW Biologics, a Phase 2 biotech developing novel immunotherapies for cancer, raised $56 million by offering 7.0 million shares at $8, the low end of the range of $8 to $10. The company had originally planned to raise $50 million, but upsized the share offering...read more
HCW Biologics, a Phase 2 biotech developing novel immunotherapies for cancer, announced terms for its IPO on Wednesday.
The Miramar, FL-based company plans to raise $50 million by offering 5.6 million shares at a price range of $8 to $10. At the midpoint of...read more
Renaissance Capital’s July IPO Market Update
55 IPOs raised $15.5 billion in the most active July since 1999 and the biggest for proceeds ever. The month’s IPOs were joined by 26 SPACs. Healthcare was the most active sector with 25 IPOs, mostly biotechs, as well as medical device makers and health...read more
US IPO Weekly Recap: Life sciences, software, and more ride the summer wave in a 19 IPO week
IPO activity continued at a record pace this past week with 19 IPOs, marking the fourth week in 2021 with at least 17 US IPOs, the most since the year 2000. With the August lull around the corner, the pipeline saw less activity than usual; five IPOs and 13 SPACs...read more
Immunotherapy biotech HCW Biologics prices IPO at $8 low end
HCW Biologics, a Phase 2 biotech developing novel immunotherapies for cancer, raised $56 million by offering 7.0 million shares at $8, the low end of the range of $8 to $10. The company had originally planned to raise $50 million, but upsized the share offering...read more
Immunotherapy biotech HCW Biologics sets terms for $50 million IPO
HCW Biologics, a Phase 2 biotech developing novel immunotherapies for cancer, announced terms for its IPO on Wednesday. The Miramar, FL-based company plans to raise $50 million by offering 5.6 million shares at a price range of $8 to $10. At the midpoint of...read more